Abeona submits BLA for pz-cel; Q3 net loss $11.8M, cash $54.1M

ABEONA THERAPEUTICS INC.

2023-Q3 EPS reported -$1.89 revenue$3,500,000

Q3 net loss $11.8M ($0.48/share) vs $6.4M ($1.00/share) in Q3 2022.
Cash and short-term investments $54.1M; estimated runway into Q4 2024.
BLA for pz-cel (gene therapy for RDEB) submitted in September; FDA decision expected late-Nov 2023.
Raised $25M in July registered direct offering; commercial launch prep underway.
Appointed Madhav Vasanthavada as Chief Commercial Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABEONA THERAPEUTICS INC. reported the third quarter of 2023 results: net income Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s, EPS $0.48 loss per common share.

Period: the third quarter of 2023
Net income: Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s
EPS: $0.48 loss per common share
Result: reported results

Exact text from the filing

Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common share as compared to a net loss attributable to common shareholders of $6.4 million, or $1.00 loss per common share, in the third quarter of 2022.

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-040318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.